

# Mothaffar F Rimawi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4447081/publications.pdf>

Version: 2024-02-01

136  
papers

7,000  
citations

61857

43  
h-index

60497

81  
g-index

139  
all docs

139  
docs citations

139  
times ranked

10101  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. <i>Cancer Research</i> , 2008, 68, 826-833.	0.4	415
2	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2615-2623.	0.8	413
3	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. <i>Cancer Research</i> , 2013, 73, 4885-4897.	0.4	394
4	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	0.8	251
5	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. <i>Journal of Clinical Oncology</i> , 2013, 31, 1726-1731.	0.8	238
6	Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 166-173.	0.8	235
7	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation. <i>Breast Cancer Research</i> , 2011, 13, R121.	2.2	219
8	Targeting HER2 for the Treatment of Breast Cancer. <i>Annual Review of Medicine</i> , 2015, 66, 111-128.	5.0	213
9	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. <i>Cancer</i> , 2010, 116, 1234-1242.	2.0	181
10	Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 694-705.	3.0	176
11	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 795-804.	1.1	175
12	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 156-163.	5.1	171
13	Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 10-20.	1.1	170
14	Towards personalized treatment for early stage HER2-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 233-250.	12.5	166
15	Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 596.	3.8	163
16	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2826-2835.	0.8	152
17	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	0.8	148
18	Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor-Positive, HER-2/neu-Positive Breast Cancer. <i>Cancer Research</i> , 2006, 66, 8266-8273.	0.4	147

#	ARTICLE	IF	CITATIONS
19	β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. <i>Breast Cancer Research</i> , 2011, 13, R84.	2.2	147
20	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 178-189.	0.8	136
21	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6600-E6609.	3.3	119
22	High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 2314-2327.	3.2	112
23	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. <i>Cancer Research</i> , 2016, 76, 6495-6506.	0.4	105
24	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26823-26834.	3.3	103
25	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1079.	0.8	102
26	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
27	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	3.4	92
28	Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor-Negative Breast Cancer. <i>Cancer Prevention Research</i> , 2012, 5, 1144-1154.	0.7	86
29	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5123-5134.	3.2	85
30	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3995-4003.	3.2	82
31	Microscaled proteogenomic methods for precision oncology. <i>Nature Communications</i> , 2020, 11, 532.	5.8	78
32	Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. <i>Clinical Cancer Research</i> , 2011, 17, 1351-1361.	3.2	76
33	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
34	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	1.1	71
35	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 399-410.	1.1	69
36	DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 189-196.	1.1	65

#	ARTICLE	IF	CITATIONS
37	Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. <i>Breast Cancer Research</i> , 2014, 16, 430.	2.2	61
38	Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 263-272.	1.1	49
39	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49
40	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	3.2	49
41	Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. <i>Breast Cancer Research</i> , 2015, 17, 3.	2.2	48
42	The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. <i>British Journal of Cancer</i> , 2019, 120, 331-339.	2.9	48
43	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. <i>Nature Medicine</i> , 2018, 24, 505-511.	15.2	47
44	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	0.9	46
45	Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. <i>Journal of Human Nutrition and Dietetics</i> , 2015, 28, 272-282.	1.3	45
46	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2318-2330.	1.5	41
47	A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 101-109.	1.1	40
48	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 821-827.	3.2	40
49	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1772.	1.0	36
50	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	0.8	36
51	Self-blame, Self-forgiveness, and Spirituality in Breast Cancer Survivors in a Public Sector Setting. <i>Journal of Cancer Education</i> , 2010, 25, 343-348.	0.6	35
52	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 1098-1105.	3.2	35
53	Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 583-593.	1.1	31
54	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 738-745.	3.2	31

#	ARTICLE	IF	CITATIONS
55	A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 819-827.	1.1	30
56	TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. <i>Clinical Cancer Research</i> , 2016, 22, 5706-5712.	3.2	30
57	Making Sense of Clinical Trial Data: Is Inverse Probability of Censoring Weighted Analysis the Answer to Crossover Bias?. <i>Journal of Clinical Oncology</i> , 2012, 30, 453-458.	0.8	26
58	Resistance to Anti-HER2 Therapies in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e157-e164.	1.8	24
59	Immunogenomic Profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 187-202.	1.1	24
60	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	0.8	22
61	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	1.1	21
62	Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. <i>BMC Cancer</i> , 2019, 19, 220.	1.1	19
63	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	1.1	19
64	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	1.7	17
65	Predictors of post-mastectomy reconstruction in an underserved population. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2013, 66, 763-769.	0.5	15
66	Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. <i>Clinical Breast Cancer</i> , 2018, 18, 78-87.	1.1	13
67	Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endocrine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. , 2015, , .		13
68	Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1104-TPS1104.	0.8	13
69	Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study. <i>Cancer Research</i> , 2022, 82, PD4-02-PD4-02.	0.4	12
70	Blocking both driver and escape pathways improves outcomes. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 133-134.	12.5	11
71	A Phase II Trial of Capecitabine Concomitantly With Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases From Breast Cancer. <i>Oncologist</i> , 2015, 20, 13-13.	1.9	11
72	Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 427-435.	1.1	11

#	ARTICLE	IF	CITATIONS
73	A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3080-3080.	0.8	10
74	Management of hormone receptorâ€“positive, human epidermal growth factor 2â€“negative metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 190, 189-201.	1.1	10
75	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. Journal of Clinical Oncology, 2018, 36, 509-509.	0.8	10
76	Elacestrant and the Promise of Oral SERDs. Journal of Clinical Oncology, 2022, 40, 3227-3229.	0.8	10
77	TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBCâ€“Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2019, 37, 507-507.	0.8	9
78	Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) ± palbociclib (P).. Journal of Clinical Oncology, 2019, 37, 570-570.	0.8	9
79	Aromatase Inhibitor Adverse Effects: Are We Sweeping Them Under the Rug?. Journal of Clinical Oncology, 2014, 32, 3779-3779.	0.8	8
80	Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked. Experimental Hematology and Oncology, 2015, 4, 1.	2.0	8
81	A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, 606-606.	0.8	8
82	Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2â€“ Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174.	3.2	8
83	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	2.3	8
84	Jejunal Intussusception Due to Malignant Phyllodes Tumor of the Breast. Clinical Breast Cancer, 2012, 12, 219-221.	1.1	6
85	Lumpectomy followed by radiation improves survival in HER2 positive and tripleâ€“negative breast cancer with high tumorâ€“infiltrating lymphocytes compared to mastectomy alone. Cancer Medicine, 2021, 10, 4790-4795.	1.3	6
86	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211071.	1.4	6
87	Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer. Pharmacotherapy, 2013, 33, 1126-1129.	1.2	5
88	Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.. Journal of Clinical Oncology, 2014, 32, 536-536.	0.8	5
89	Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physicianâ€™s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC). Cancer Research, 2022, 82, OT2-11-09-OT2-11-09.	0.4	5
90	Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. Npj Breast Cancer, 2021, 7, 63.	2.3	4



#	ARTICLE	IF	CITATIONS
91	Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003. , 2015, , .		4
92	Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).. Journal of Clinical Oncology, 2012, 30, TPS654-TPS654.	0.8	4
93	TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.. Journal of Clinical Oncology, 2018, 36, 511-511.	0.8	4
94	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 1011-1011.	0.8	4
95	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	0.8	3
96	Abstract PD3-09:HER2 L755Smutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models. , 2021, , .		2
97	Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.. Journal of Clinical Oncology, 2017, 35, 10088-10088.	0.8	2
98	Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions. Current Problems in Cancer, 2016, 40, 117-129.	1.0	1
99	Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Current Problems in Cancer Case Reports, 2020, 2, 100034.	0.1	1
100	TBCRC-010: Phase I/II study of dasatinib in combination with zoledronic acid (ZA) for the treatment of breast cancer bone metastasis (MBC-bone).. Journal of Clinical Oncology, 2015, 33, 11080-11080.	0.8	1
101	Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 608-608.	0.8	1
102	Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial.. Journal of Clinical Oncology, 2017, 35, 513-513.	0.8	1
103	TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)â€”Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2014, 32, TPS1145-TPS1145.	0.8	1
104	Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52. , 2019, , .		1
105	Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Cancer Research, 2022, 82, OT1-14-02-OT1-14-02.	0.4	1
106	Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer. Cancer Research, 2022, 82, PD8-06-PD8-06.	0.4	1
107	Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of <i>HER</i> and <i>PIK3CA</i> mutations and development of new treatment strategies and study models. Cancer Research, 2022, 82, P4-01-01-P4-01-01.	0.4	1
108	A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.. Journal of Clinical Oncology, 2022, 40, TPS1110-TPS1110.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Challenges in the treatment of younger women with breast cancer. <i>Breast Cancer Management</i> , 2012, 1, 127-134.	0.2	0
110	Retrospective review of genomic testing in breast cancer: Does it improve outcome?. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 191-195.	1.1	0
111	Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC). , 2021, , .		0
112	Abstract P33: Disparities in breast cancer screening and the impact of COVID-19 in Houston, Texas. , 2021, , .		0
113	Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10587-10587.	0.8	0
114	Change in management based on actionable mutations in metastatic breast cancer in an ethnically diverse cohort: Single institution experience.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13067-e13067.	0.8	0
115	A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS604-TPS604.	0.8	0
116	Abstract CT256: A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer. , 2021, , .		0
117	Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance. , 2021, , .		0
118	Abstract LB-305: Circulating tumor cells as a novel model to test efficacy of individualized therapy in breast cancer. , 2012, , .		0
119	Scalp cooling alopecia prevention trial (SCALP).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9660-TPS9660.	0.8	0
120	Abstract CT319: A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors. , 2014, , .		0
121	Abstract P5-05-03: Clonal evolution of the HER2 L755S mutation leads to acquired HER-targeted therapy resistance that can be reversed by the irreversible HER1/2 inhibitor afatinib. , 2015, , .		0
122	Abstract P4-01-06: Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. , 2015, , .		0
123	Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8. , 2015, , .		0
124	Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS10144-TPS10144.	0.8	0
125	Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10020-10020.	0.8	0
126	Abstract 4827: The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models. , 2019, , .		0



#	ARTICLE	IF	CITATIONS
127	Abstract P5-14-02: Breast cancer clinical trial participation rate among patients of low socioeconomic status at a comprehensive cancer center. Cancer Research, 2022, 82, P5-14-02-P5-14-02.	0.4	0
128	Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET. Cancer Research, 2022, 82, PD2-07-PD2-07.	0.4	0
129	Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer. Cancer Research, 2022, 82, PD1-05-PD1-05.	0.4	0
130	Abstract OT1-18-07: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy. Cancer Research, 2022, 82, OT1-18-07-OT1-18-07.	0.4	0
131	Abstract PD15-03: Overlapping molecular features (proliferation, immune signatures) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 587 Cancer Research, 2022, 82, PD15-03-PD15-03.	0.4	0
132	Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer. Cancer Research, 2022, 82, P5-07-01-P5-07-01.	0.4	0
133	Abstract P2-09-09: Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience. Cancer Research, 2022, 82, P2-09-09-P2-09-09.	0.4	0
134	Abstract 4757: Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy. , 2019, , .		0
135	Abstract CT232: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01. Cancer Research, 2022, 82, CT232-CT232.	0.4	0
136	Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.. Journal of Clinical Oncology, 2022, 40, 522-522.	0.8	0